161Tb-PSMA radioligand therapy in prostate cancer: current evidence and future perspectives

Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein, is overexpressed on the membranes of prostate cancer cells. Lutetium-177 (177Lu)- labelled PSMA-targeted radioligand therapy (PRLT) is employed in treating metastatic castration-resistant prostate cancer (mCRPC) that no...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Liming Xiao, Ziyi Zhao, Rui Luo, Fucen Liu, Bosen Hu, Peng Zhao, Xia Yang, Zhengguo Chen
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Frontiers Media S.A. 2026-01-01
Цуврал:	Frontiers in Oncology
Нөхцлүүд:	dosimetry lutetium-177 (177Lu) metastatic castration-resistant prostate cancer(mCRPC) prostate-specific membrane antigen (PSMA) PSMA-targeted radioligand therapy (PRLT) radiopharmaceuticals
Онлайн хандалт:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1743628/full
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!